ContentsSynopsisCodesLook ForDiagnostic PearlsDifferential Diagnosis & PitfallsBest TestsManagement PearlsTherapyDrug Reaction DataReferencesView all Images (17)
Drug-induced flagellate pigmentation in Adult
Print
Other Resources UpToDate PubMed

Drug-induced flagellate pigmentation in Adult

Print Images (17)
Contributors: Susan Burgin MD
Other Resources UpToDate PubMed

Synopsis

Flagellate erythema and flagellate pigmentation are well-known cutaneous complications following bleomycin sulfate therapy. Studies have shown an incidence rate of 8%-66% of patients on bleomycin developing this patterned eruption. The dose of bleomycin required to produce such an effect is usually more than 100 U, and eruptions are considered to be dose dependent. However, reactions have been seen with doses as low as 15 U intravenously (IV) and 30 U intrapleurally. Intraperitoneal and intramuscular injection have also produced the eruption, as have intralesional bleomycin given for venous malformation sclerosis and intralesional therapy for wart treatment. Other chemotherapeutic agents including peplomycin, bendamustine, docetaxel, cisplatin, and trastuzumab are additional causes of flagellate erythema and pigmentation.

Flagellate erythema appears as linear, whip-like, erythematous streaks on the upper torso and, less frequently, on the extremities. The eruption may be preceded by severe, generalized pruritus and is itself usually very pruritic. Flagellate erythema may occur within 24 hours of receiving the culprit medication, or there may be a lag time of up to 6 months. It has a self-limited course and usually subsides, leaving a residual postinflammatory hyperpigmentation that may persist for months. In some cases, patients note minimal or absent pruritus or erythema, and hyperpigmentation is the initial presentation.

The pathogenesis of flagellate erythema is unclear. Scratching is thought to disrupt the dermal vasculature with subsequent drug leakage into the dermis. Bleomycin is metabolized by bleomycin hydrolase in the subcorneal layer. This enzyme is absent from the dermis and so the drug might accumulate there and cause its toxic effects. Immunologic mechanisms, including type I and type II responses, have also been postulated.

Pediatric Patient Considerations
Bleomycin-induced flagellate erythema and pigmentation have been reported in the pediatric population as well.

Codes

ICD10CM:
T50.995A – Adverse effect of other drugs, medicaments and biological substances, initial encounter

SNOMEDCT:
110284009 – Drug-induced pigmentation

Look For

Subscription Required

Diagnostic Pearls

Subscription Required

Differential Diagnosis & Pitfalls

Flagellate erythema:
Flagellate pigmentation:

Best Tests

Subscription Required

Management Pearls

Subscription Required

Therapy

Subscription Required

Drug Reaction Data

Below is a list of drugs with literature evidence indicating an adverse association with this diagnosis. The list is continually updated through ongoing research and new medication approvals. Click on Citations to sort by number of citations or click on Medication to sort the medications alphabetically.

Subscription Required

References

Subscription Required

Last Reviewed: 03/09/2018
Last Updated: 03/09/2018
Copyright © 2018 VisualDx®. All rights reserved.
Drug-induced flagellate pigmentation in Adult
Print 17 Images Filter Images
View all Images (17)
(with subscription)
 Reset
Drug-induced flagellate pigmentation : bendamustine, bleomycin, docetaxel, Hyperpigmented patch, Linear configuration, Superior chest, Upper back
Clinical image of Drug-induced flagellate pigmentation
Copyright © 2018 VisualDx®. All rights reserved.